JB Chemicals Peer Comparison

NSE: JBCHEPHARM | BSE: 506943

₹2,408.90

₹-97.10 (-3.87%)

As on 16-Jul-2026IST

Market cap

₹38,731 Cr

Revenue (TTM)

₹4,148 Cr

P/E Ratio

54.6

P/B Ratio

9.3

Div. Yield

0.9 %

Edit

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	38,731	21,330	20,606	17,990	17,318
Revenue (₹ Cr)	4,148	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	709.47	735.15	678.07	666.92	169.62
Net Margin (%)	16.85	26.88	28.10	20.60	6.90
RoE (%)	19.11	19.16	19.73	18.75	20.76
Price to Earnings	54.59	29.01	30.97	27.94	102.10
Price-To-Book	9.31	4.84	5.47	4.45	19.15

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	4,147.79	2,519.65	--	--	2,275.58
Total Income	4,209.62	2,707.60	--	--	2,304.07
Total Expenditure	3,042.03	1,615.47	--	--	2,013.55
EBITDA	1,105.76	904.18	--	--	262.03
Depreciation	182.50	57.73	--	--	28.58
EBIT	923.26	846.45	--	--	233.45
Interest	5.57	9.57	--	--	4.49
Other Income	61.82	187.95	--	--	28.49
Exceptional Items	-27.18	-49.16	--	--	-5.25
Profit before Tax	952.34	975.67	--	--	252.20
Provision for Tax	242.86	253.24	--	--	64.68
Profit after Tax	709.47	722.43	--	--	187.52

Liabilities (₹ Cr)

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	4,159.22	4,202.90	--	--	872.79
Minority Interest	--	--	--	--	--
Non-Current Liabilities	679.04	19.19	--	--	394.49
Current Liabilities	1,037.35	627.48	--	--	1,109.50
Total Liabilities	5,875.61	4,921.88	--	--	2,414.58

Assets (₹ Cr)

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	2,520.05	1,046.35	--	--	509.16
Current Assets	3,355.56	3,803.22	--	--	1,859.88
Total Assets	5,875.61	4,921.88	--	--	2,414.58
Total Debt*	0.00	2.50	--	--	0.00
Net Current Assets	2,318.21	3,175.74	--	--	750.38
Contingent Liabilities	106.98	370.49	--	--	121.23

Cashflow (₹ Cr)

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	703.92	967.57	--	--	-15.14
Cash Flow from Investing Activities	-585.88	-561.67	--	--	18.69
Cash from Financing Activities	-123.10	-798.31	--	--	-91.97
Net Cash Inflow / Outflow	-5.05	-392.41	--	--	-88.42

Ratios

Profitability Ratios

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	25.19	23.39	--	--	31.24
ROE (%)	19.11	17.16	--	--	23.02
ROA (%)	13.01	14.91	--	--	8.90
EBIT Margin (%)	28.15	43.34	--	--	12.77
Net Margin (%)	16.85	26.68	--	--	8.14
Cash Profit Margin (%)	20.80	29.72	--	--	9.47

Growth Ratios

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	5.87	10.45	--	--	32.59
EBIT Growth (%)	9.10	19.68	--	--	-1.38
Net Profit Growth (%)	7.56	-5.88	--	--	62.02
EPS Growth (%)	4.29	-5.88	--	--	62.02
Book Value Growth (%)	27.38	-0.34	--	--	13.51

Valuation Ratios

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	46.69	29.89	--	--	103.45
Price / Book Value	7.96	5.14	--	--	22.39
Dividend Yield (%)	1.07	1.59	--	--	0.46
EV/EBITDA	28.25	16.93	--	--	65.23
Market Cap (₹ Cr)	33,126.34	21,592.90	--	--	19,398.64

Solvency Ratios

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.00	0.00	--	--	0.00
Short term debt to equity ratio	--	0.00	--	--	--
Current Ratio	3.23	6.06	--	--	1.68
Quick Ratio	2.58	5.31	--	--	0.75
Interest Coverage	172.03	102.95	--	--	57.17

Operating Efficiency Ratios

	JB Chemicals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	18.83	7.22	--	--	9.39
Asset Turnover	0.79	0.54	--	--	1.08
Receivable days	67.92	26.06	--	--	31.88
Inventory Days	51.58	65.95	--	--	126.03
Payable days	112.87	81.01	--	--	163.79
Cash Conversion Cycle	6.63	11.00	--	--	-5.88